NATCOPHARM.BONATCOPHARM.BOBSE
Loading
EBITDA Over TimeExpanding
Percentile Rank100
3Y CAGR+102.0%
5Y CAGR+29.8%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+102.0%/yr
vs -27.2%/yr prior
5Y CAGR
+29.8%/yr
Recent acceleration
Acceleration
+129.3pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
3.7x
Strong expansion
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$21.44B+22.5%
2024$17.51B+81.1%
2023$9.67B+271.9%
2022$2.60B-57.1%
2021$6.07B+4.2%
2020$5.82B-26.7%
2019$7.95B-14.2%
2018$9.27B+35.4%
2017$6.84B+155.0%
2016$2.68B-